MX367209B - Una composición intravenosa que comprende ibuprofeno y paracetamol en combinación. - Google Patents

Una composición intravenosa que comprende ibuprofeno y paracetamol en combinación.

Info

Publication number
MX367209B
MX367209B MX2015008709A MX2015008709A MX367209B MX 367209 B MX367209 B MX 367209B MX 2015008709 A MX2015008709 A MX 2015008709A MX 2015008709 A MX2015008709 A MX 2015008709A MX 367209 B MX367209 B MX 367209B
Authority
MX
Mexico
Prior art keywords
paracetamol
combination
composition including
intravenous composition
including ibuprofen
Prior art date
Application number
MX2015008709A
Other languages
English (en)
Inventor
Campbell Atkinson Hartley
Original Assignee
Aft Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46024668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX367209(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aft Pharmaceuticals Ltd filed Critical Aft Pharmaceuticals Ltd
Publication of MX367209B publication Critical patent/MX367209B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Una composición intravenosa para proporcionar alivio del dolor y/o la inflamación, conteniendo la composición ibuprofeno y paracetamol combinados para suministrar a un ser humano en cada dosis: a) de aproximadamente 125 mg a aproximadamente 175 mg de ibuprofeno combinados con de aproximadamente 475 mg a aproximadamente 525 mg de paracetamol; o b) de aproximadamente 275 mg a aproximadamente 325 mg de ibuprofeno combinados con de aproximadamente 975 mg a aproximadamente 1025 mg de paracetamol.
MX2015008709A 2010-11-04 2011-10-26 Una composición intravenosa que comprende ibuprofeno y paracetamol en combinación. MX367209B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ58901110 2010-11-04
PCT/NZ2011/000226 WO2012060719A1 (en) 2010-11-04 2011-10-26 A combination composition

Publications (1)

Publication Number Publication Date
MX367209B true MX367209B (es) 2019-07-22

Family

ID=46024668

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013005113A MX2013005113A (es) 2010-11-04 2011-10-26 Una composicion combinada.
MX2015008709A MX367209B (es) 2010-11-04 2011-10-26 Una composición intravenosa que comprende ibuprofeno y paracetamol en combinación.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2013005113A MX2013005113A (es) 2010-11-04 2011-10-26 Una composicion combinada.

Country Status (28)

Country Link
US (6) US20130225685A1 (es)
EP (1) EP2635269B1 (es)
JP (2) JP2013541583A (es)
KR (1) KR101900520B1 (es)
CN (2) CN107519159A (es)
AU (1) AU2011324137B2 (es)
BR (1) BR112013010829B8 (es)
CA (1) CA2814057C (es)
CL (1) CL2013001250A1 (es)
CO (1) CO6771406A2 (es)
CY (1) CY1123398T1 (es)
DK (1) DK2635269T3 (es)
ES (1) ES2742373T3 (es)
HR (1) HRP20191489T1 (es)
HU (1) HUE045442T2 (es)
LT (1) LT2635269T (es)
MX (2) MX2013005113A (es)
MY (1) MY160572A (es)
NZ (1) NZ609727A (es)
PH (2) PH12013500689A1 (es)
PL (1) PL2635269T3 (es)
PT (1) PT2635269T (es)
RS (1) RS59258B1 (es)
RU (2) RU2013123646A (es)
SG (1) SG189319A1 (es)
SI (1) SI2635269T1 (es)
SM (1) SMT201900481T1 (es)
WO (1) WO2012060719A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011324137B2 (en) 2010-11-04 2015-05-07 Aft Pharmaceuticals Limited A combination composition
US9072710B2 (en) 2012-03-16 2015-07-07 Cumberland Pharmaceuticals Inc. Injectable ibuprofen formulation
WO2016008546A1 (en) * 2014-07-18 2016-01-21 Everbright Pharmaceuticals S.A.R.L. Aqueous formulation comprising paracetamol and ibuprofen
EP3203996A4 (en) * 2014-10-06 2018-05-16 Cumberland Pharmaceuticals, Inc. Co-administration of intravenous ibuprofen and acetaminophen for treatment of pain
WO2018192664A1 (en) 2017-04-20 2018-10-25 Hyloris Developments Sa METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF
KR102642847B1 (ko) * 2017-07-10 2024-03-04 젤 캡 테크놀로지스 엘엘씨 이중 방출 투여형 캡슐 및 이를 제조하기 위한 방법, 장치 및 시스템
US11197830B2 (en) 2019-02-27 2021-12-14 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetaminophen and ibuprofen
US11568752B2 (en) * 2020-01-28 2023-01-31 David Clark Company Incorporated Gateway retrieval alert device for aircraft pushback operations
WO2023281089A2 (en) 2021-07-08 2023-01-12 Krka, D.D., Novo Mesto Pharmaceutical composition comprising naproxen and paracetamol
GR1010809B (el) * 2023-09-13 2024-10-25 Ιουλια Τσετη Υδατικο διαλυμα ιβουπροφαινης παρακεταμολης για χρηση σε ενδοφλεβια χορηγηση
GR1010769B (el) * 2023-07-27 2024-09-18 Ιουλια Κλεωνος Τσετη Υδατικο διαλυμα ιβουπροφαινης για χρηση σε ενδοφλεβια χορηγηση
AU2024281739A1 (en) 2023-06-02 2025-11-27 Ioulia Tseti Pharmaceutical composition comprising ibuprofen

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3990895A (en) * 1995-12-05 1997-06-27 Adcock Ingram Limited Pharmaceutical composition comprising a skeletal muscle relaxant, a non-steroidal antiinflammatory agent and an analgesic
KR100851679B1 (ko) * 2001-11-02 2008-08-13 큠버랜드 파마슈티컬즈 인코포레이티드 2-(4-이소부틸페닐)프로피온산의 약학 조성물
JP2006514982A (ja) * 2003-03-21 2006-05-18 マクニール−ピーピーシー・インコーポレイテッド 非ステロイド抗炎症薬投薬計画
EP1781277B1 (en) * 2004-07-07 2012-02-01 AFT Pharmaceuticals Limited A combination composition comprising ibuprofen and paracetamol
KR20060072839A (ko) * 2004-12-23 2006-06-28 김경태 아세트아미노펜과 이부프로펜을 이용하여 통증조절과 해열작용을 하는 주사제
US7934627B2 (en) * 2005-10-13 2011-05-03 Alcoa Inc. Apparatus and method for high pressure extrusion with molten aluminum
MX2009004203A (es) * 2006-10-20 2009-07-02 Mcneil Ppc Inc Combinaciones de paracetamol/ibuprofeno y metodo para su uso.
WO2008079818A2 (en) * 2006-12-21 2008-07-03 Soluprin Pharmaceuticals, Inc. Intravenous administration of water soluble analgesic formulations
US20090264530A1 (en) * 2008-04-16 2009-10-22 Nickell Robert P Combined nsaid and acetaminophen formulation and method
HRP20190891T1 (hr) * 2008-10-14 2019-07-12 Aft Pharmaceuticals Limited Medicinski proizvod i tretman
WO2010105129A1 (en) * 2009-03-12 2010-09-16 Cumberland Pharmaceuticals Administration of intravenous ibuprofen
NZ604009A (en) * 2010-07-07 2015-03-27 Aft Pharmaceuticals Ltd A combination composition comprising ibuprofen and paracetamol
AU2011324137B2 (en) 2010-11-04 2015-05-07 Aft Pharmaceuticals Limited A combination composition
EP3203996A4 (en) * 2014-10-06 2018-05-16 Cumberland Pharmaceuticals, Inc. Co-administration of intravenous ibuprofen and acetaminophen for treatment of pain

Also Published As

Publication number Publication date
CA2814057C (en) 2022-02-01
US11446266B2 (en) 2022-09-20
AU2011324137A1 (en) 2013-05-02
US20190029982A1 (en) 2019-01-31
US12220392B2 (en) 2025-02-11
PH12021550804A1 (en) 2022-02-14
CY1123398T1 (el) 2021-10-29
JP2013541583A (ja) 2013-11-14
US20160235695A1 (en) 2016-08-18
HRP20191489T1 (hr) 2019-11-15
ES2742373T3 (es) 2020-02-14
CA2814057A1 (en) 2012-05-10
RU2015103107A3 (es) 2018-08-20
PH12013500689A1 (en) 2013-05-27
US20250134839A1 (en) 2025-05-01
AU2011324137B2 (en) 2015-05-07
MY160572A (en) 2017-03-15
US20240207210A1 (en) 2024-06-27
WO2012060719A1 (en) 2012-05-10
CL2013001250A1 (es) 2013-08-30
SI2635269T1 (sl) 2019-10-30
LT2635269T (lt) 2019-09-10
DK2635269T3 (da) 2019-08-26
BR112013010829A2 (pt) 2016-08-16
EP2635269A1 (en) 2013-09-11
KR20140025314A (ko) 2014-03-04
RU2707089C2 (ru) 2019-11-22
MX2013005113A (es) 2013-06-03
RU2013123646A (ru) 2014-12-10
US20230000805A1 (en) 2023-01-05
RS59258B1 (sr) 2019-10-31
CN107519159A (zh) 2017-12-29
BR112013010829B8 (pt) 2022-01-04
JP2017132791A (ja) 2017-08-03
HUE045442T2 (hu) 2019-12-30
PL2635269T3 (pl) 2019-11-29
CO6771406A2 (es) 2013-10-15
CN103298464A (zh) 2013-09-11
PT2635269T (pt) 2019-09-04
RU2015103107A (ru) 2015-06-20
EP2635269B1 (en) 2019-05-22
SG189319A1 (en) 2013-05-31
SMT201900481T1 (it) 2019-11-13
NZ609727A (en) 2015-07-31
US11896567B2 (en) 2024-02-13
KR101900520B1 (ko) 2018-09-19
EP2635269A4 (en) 2014-09-17
BR112013010829B1 (pt) 2021-12-21
JP6353577B2 (ja) 2018-07-04
US20130225685A1 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
MX367209B (es) Una composición intravenosa que comprende ibuprofeno y paracetamol en combinación.
EA201290833A1 (ru) Применение амисульприда в качестве противорвотного средства
CR11724A (es) Agente para tratar enfermedades
CO6311006A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+ efectiva a dosis altas
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
CO6382132A2 (es) Tratamiento de pirfenidona para pacientes con funcion hepatica atipica
AR089509A1 (es) Metodo para tratar la perdida osea alveolar, un implante dental, un anticuerpo antiesclerostina, un gel o matriz que comprende dicho anticuerpo y uso
CO2019000938A2 (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos
UY31205A1 (es) Composiciones de tabletas de desintegracion oral de lamotrigina
MX2015009772A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
MX2009011444A (es) Titulacion del tapentadol.
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
PE20211199A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
ECSP10010567A (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de dronedarona
MY164112A (en) A combination composition comprising ibuprofen and paracetamol
DOP2016000008A (es) Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio
MX2009008813A (es) Composicion farmaceutica que contiene floroglucinol y paracetamol.
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
CL2012003065A1 (es) Combinación farmacéutica que comprende ibuprofeno y l-arginina en una proporción en peso de ibuprofeno/l-arginina entre 1.6 y 5.6, con excepción del valor 1.97; composición farmacéutica sólida que contiene a dicha combinación; y su uso en el tratamiento del dolor, inflamación y/o fiebre.
AR061046A1 (es) Mirtazapina para el tratamiento del dolor neuropatico
MX2022012260A (es) Compuestos activos frente a receptores nucleares.
TH152432A (th) องค์ประกอบแบบผสมผสาน
CL2012003685A1 (es) Kit farmaceutico que comprende una o mas unidades de envasado que comprenden 21 a 28 unidades de dosificacion activas diarias en que cada una comprende por lo menos 2 mg de drosperidona, sin estrogernos; uso del kit y de una composicion farmaceutica que comprende drosperidona para preparar un medicamento util como anticonceptivo.
UY32985A (es) Uso de celivarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de celivarona
AR091633A1 (es) Solucion inyectable de acetaminofen para su administracion por via espinal